Qube Research & Technologies LTD Bio Line Rx Ltd. Put Options Transaction History
Qube Research & Technologies LTD
- $62.3 Billion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding BLRX
# of Institutions
37Shares Held
4.29MCall Options Held
49.9KPut Options Held
122K-
Alyeska Investment Group, L.P. Chicago, IL1.95MShares$1.27 Million0.01% of portfolio
-
Cvi Holdings, LLC Wilmington, DE816KShares$530,1934.05% of portfolio
-
Envestnet Asset Management Inc214KShares$138,9910.0% of portfolio
-
Values First Advisors, Inc.204KShares$132,4430.07% of portfolio
-
Pvg Asset Management Corp Golden, CO124KShares$80,3270.3% of portfolio
About BioLineRx Ltd.
- Ticker BLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,524,500
- Market Cap $40M
- Description
- BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...